위암환자의 혈청 CEA , CA19 - 9 및 AFP 에 관한 연구

Objectives: For the diagnosis and evaluation of gastric cancer, various methods including upper GI series, endoscopy, ultrasound, CAT scan are used with serum tumor markers, especially CEA, CA19-9 and AFP. Although many studies were done to evaluate the clinical usefulness of serum tumor markers for the diagnosis and management of gastrointestinal cancer, the studies which was done in depth on gastric cancer alone were few. In this study we, therefore, evaluated clinical significance of serum CEA, CA19-9 and AFP of 712 gastric cancer patients for the diagnosis and management of gastric cancer. Methods: Serum levels of CEA, CA19-9 and AFP were measured in 712 eases of gastric cancer including 346 operative cases to evaluate the clinical usefulness of these markers for the diagnosis and management of gastric cancer. The cutoff level of serum CEA, CA19-9 and AFP were 10 ng/ml, 37 U/ml and 20 ng/ml, respectively. The serum levels were correlated with the stage, the location, the gross type, the depth of invasion, the nodal and distant metastasis. AFP-positive cases were analysed seperately and immunohistochemical staining was done to asses the presence of AFP, EGF and TGF β in the cancer tissue. Results: 1) Overall positivity of CEA, CA19-9 and AFP was 27.8% (198 cases), 32.7%; (233 cases) and 5.6% (30 cases/540 cases), respectively. 2) There was no difference in the positivity of serum CEA and CA19-9 according to locations and gross types of the cancer, but significant (p